Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer

1 year ago 80

MONDAY, April 22, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Alecensa (alectinib) as adjuvant treatment following tumor...

1. Homepage
2. Lung Cancer
3. Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer